The effects of somatic hypermutation on neutralizing and binding in the PGT121 family of broadly neutralizing antibodies.

/in

Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P. The effects of somatic hypermutation on neutralizing and binding in the PGT121 family of broadly neutralizing antibodies. PLoS Pathog. 2013, 9(11):e1003754.

Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.

/in

Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl. Acad. Sci. 2013, 110(33):13540-5.

The production, characterization and application of monoclonal antibodies generated by immunization with HIV-1C clade RGP140 envelope protein.

/in

Hassall M, Page M, Robinson M, Jeffs S, Jones I, Chen H, Seaman MS, Ferguson D, Almond N. The production, characterization and application of monoclonal antibodies generated by immunization with HIV-1C clade RGP140 envelope protein. J. Virol. Methods. 2013, 194(1-2):89-93.

Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

/in , ,

Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis. 2013; 207:248-256.

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

/in , , ,

Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.

Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.

/in

Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK. Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data. PLoS One. 2013, 8(12):e80562.

Vaccine delivery with microneedle skin patches in nonhuman primates.

/in ,

DeMuth PC, Li AV, Abbink P, Liu J, Li J, Stanley KA, Smith KM, Lavine CL, Seaman MS, Kramer JA, Miller AD, Abraham W, Suh H, Elkhader J, Hammond PT, Barouch DH, Irvine DJ. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat. Biotech. 2013; 31:1082-1085.

Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-clade B HIV-1 infected individuals.

/in

Andrabi R, Williams C, Wang XH, Li L, Choudhary AK, Wig N, Biswas A, Luthra K, Nadas A, Seaman MS, Nyambi P, Zolla Pazner S, Gorny MK. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-clade B HIV-1 infected individuals. Virology. 2013, 439(2): 81-8.

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

/in

Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, Devico AL, Lewis GK. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl. Acad. Sci. 2013, 110(1): E69-78.

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

/in , ,

Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 2013; 207:240-247.